A Kelch domain-containing KLHDC7B and a long non-coding RNA ST8SIA6-AS1 act oppositely on breast cancer cell proliferation via the interferon signaling pathway
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Kelch domain-containing KLHDC7B and a long non-coding RNA ST8SIA6-AS1 act oppositely on breast cancer cell proliferation via the interferon signaling pathway
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-21
DOI
10.1038/s41598-018-31306-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Functional Classification and Experimental Dissection of Long Noncoding RNAs
- (2018) Florian Kopp et al. CELL
- Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma
- (2017) Yingyun Yang et al. HEPATOLOGY
- Goose Mx and OASL Play Vital Roles in the Antiviral Effects of Type I, II, and III Interferon against Newly Emerging Avian Flavivirus
- (2017) Shun Chen et al. Frontiers in Immunology
- Epigenetically regulated Fibronectin leucine rich transmembrane protein 2 (FLRT2) shows tumor suppressor activity in breast cancer cells
- (2017) Hansol Bae et al. Scientific Reports
- Regulation of theMEToncogene: molecular mechanisms
- (2016) Jack Zhang et al. CARCINOGENESIS
- Downregulation of miR-129-2 by promoter hypermethylation regulates breast cancer cell proliferation and apoptosis
- (2016) XIAOFENG TANG et al. ONCOLOGY REPORTS
- Control of glioma cell migration and invasiveness by GDF-15
- (2016) Paula Codó et al. Oncotarget
- A lincRNA connected to cell mortality and epigenetically-silenced in most common human cancers
- (2015) Lukas Vrba et al. Epigenetics
- Effect of 3-bromopyruvate acid on the redox equilibrium in non-invasive MCF-7 and invasive MDA-MB-231 breast cancer cells
- (2015) Ewa Kwiatkowska et al. JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
- Current and emerging breast cancer biomarkers
- (2015) Maryam Sana et al. Journal of Cancer Research and Therapeutics
- MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma
- (2015) Zhengming Su et al. Molecular Medicine Reports
- The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment
- (2014) Clémence Basse et al. INTERNATIONAL JOURNAL OF CANCER
- LincRNA-p21 Activates p21 In cis to Promote Polycomb Target Gene Expression and to Enforce the G1/S Checkpoint
- (2014) Nadya Dimitrova et al. MOLECULAR CELL
- Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer
- (2014) Rui Huang et al. PLoS One
- IFITs: Emerging Roles as Key Anti-Viral Proteins
- (2014) Gregory I. Vladimer et al. Frontiers in Immunology
- Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer
- (2013) Tae Woo Kim et al. BMC CANCER
- 2′-5′ oligoadenylate synthetase 1 polymorphism is associated with prostate cancer
- (2011) Sanjay Mandal et al. CANCER
- Epigenetically Deregulated microRNA-375 Is Involved in a Positive Feedback Loop with Estrogen Receptor in Breast Cancer Cells
- (2010) P. de Souza Rocha Simonini et al. CANCER RESEARCH
- Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
- (2010) Rajnish A. Gupta et al. NATURE
- Inhibition of Tumor Cell Motility by the Interferon-inducible GTPase MxA
- (2009) J. Frederic Mushinski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer
- (2008) M Mourtada-Maarabouni et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More